全文获取类型
收费全文 | 1327篇 |
免费 | 70篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 31篇 |
儿科学 | 12篇 |
妇产科学 | 30篇 |
基础医学 | 177篇 |
口腔科学 | 37篇 |
临床医学 | 66篇 |
内科学 | 360篇 |
皮肤病学 | 121篇 |
神经病学 | 116篇 |
特种医学 | 50篇 |
外科学 | 154篇 |
综合类 | 5篇 |
预防医学 | 45篇 |
眼科学 | 20篇 |
药学 | 68篇 |
中国医学 | 4篇 |
肿瘤学 | 110篇 |
出版年
2023年 | 9篇 |
2022年 | 15篇 |
2021年 | 23篇 |
2020年 | 13篇 |
2019年 | 21篇 |
2018年 | 20篇 |
2017年 | 25篇 |
2016年 | 32篇 |
2015年 | 27篇 |
2014年 | 26篇 |
2013年 | 60篇 |
2012年 | 89篇 |
2011年 | 104篇 |
2010年 | 51篇 |
2009年 | 44篇 |
2008年 | 88篇 |
2007年 | 84篇 |
2006年 | 93篇 |
2005年 | 90篇 |
2004年 | 99篇 |
2003年 | 82篇 |
2002年 | 94篇 |
2001年 | 20篇 |
2000年 | 13篇 |
1999年 | 13篇 |
1998年 | 22篇 |
1997年 | 21篇 |
1996年 | 12篇 |
1995年 | 14篇 |
1994年 | 9篇 |
1993年 | 8篇 |
1992年 | 5篇 |
1991年 | 12篇 |
1990年 | 5篇 |
1989年 | 6篇 |
1988年 | 5篇 |
1987年 | 6篇 |
1986年 | 5篇 |
1985年 | 4篇 |
1984年 | 4篇 |
1983年 | 5篇 |
1982年 | 5篇 |
1981年 | 5篇 |
1978年 | 3篇 |
1977年 | 3篇 |
1974年 | 2篇 |
1971年 | 1篇 |
1969年 | 1篇 |
1968年 | 1篇 |
1962年 | 2篇 |
排序方式: 共有1406条查询结果,搜索用时 15 毫秒
51.
Yoshihito Uchida Masamitsu Nakao Shohei Tsuji Hayato Uemura Jun-ichi Kouyama Kayoko Naiki Daisuke Motoya Kayoko Sugawara Nobuaki Nakayama Yukinori Imai Tomoaki Tomiya Satoshi Mochida 《Journal of medical virology》2020,92(3):329-338
The significance of switching of the nucleos(t)ide analog used to treat patients with hepatitis B virus (HBV) from entecavir (ETV) to tenofovir alafenamide fumarate (TAF) is uncertain. The subjects of this study were 159 patients with HBV who received treatment with ETV followed by TAF. Among these patients, serial changes in the HBV marker levels were monitored in 92 patients in whom the serum HBsAg levels were ≥100 IU/mL during the 48-week period immediately before and after the switching. A questionnaire survey for medication compliance was performed in 127 patients. The serum HBsAg levels (log IU/mL) decreased by 0.041 during the ETV treatment period and by 0.068 during the TAF administration period. The degree of reduction was higher during the TAF administration period than during the ETV administration period in patients without cirrhosis (P = .030), patients with genotype B HBV (P = .014), and patients with undetectable serum HBcrAg (P = .038). Multivariate analysis revealed the HBV genotype (B vs C; odds ratio, 3.400; P = .025) and serum aspartate aminotransferase level (every 1+; 1.111; P = .015) at the time of switching as factors influencing the treatment efficacy. Thirty-six patients (28%) responded that the number of days that they forgot to take the drug decreased after the drug switching, and 77 patients (61%) reported feeling satisfied with the drug switching. Switching of the nucleos(t)ide analog used from ETV to TAF may be useful in the treatment of patients with HBV infection, as it is associated with both a decrease in the serum HBsAg level and improvement of the medication compliance. 相似文献
52.
CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells 总被引:2,自引:0,他引:2
Harata M Soda Y Tani K Ooi J Takizawa T Chen M Bai Y Izawa K Kobayashi S Tomonari A Nagamura F Takahashi S Uchimaru K Iseki T Tsuji T Takahashi TA Sugita K Nakazawa S Tojo A Maruyama K Asano S 《Blood》2004,104(5):1442-1449
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL) have poor prognosis despite intensive therapeutic intervention. Recently, imatinib, a BCR-ABL tyrosine kinase inhibitor, has been proven to be an effective treatment for Ph(+) ALL, but nearly all patients rapidly acquire resistance. High-dose imatinib administration might overcome this resistance; however, systemic toxicities would likely limit this approach. Therefore, a new delivery system allowing for the specific targeting of imatinib is urgently needed. Because almost all Ph(+) ALL cells express CD19 on their surface, we have developed an immunoliposome carrying anti-CD19 antibody (CD19-liposomes). The internalization efficiency of the CD19-liposomes approached 100% in all Ph(+) ALL cells but was very low in CD19(-) cells. The cytocidal effect of imatinib-encapsulated CD19-liposomes (imatinib-CD19-liposomes) on Ph(+) ALL cell lines and primary leukemia cells from patients with Ph(+) ALL was much greater than that of imatinib with or without control liposomes. Importantly, the imatinib-CD19-liposomes did not affect the colony formation of CD34(+) hematopoietic cells, even at inhibitory concentration of free imatinib. Taken together, these data clearly demonstrate that the imatinib-CD19-liposomes induced specific and efficient death of Ph(+) ALL cells. This new therapeutic approach might be a useful treatment for Ph(+) ALL with fewer side effects than free imatinib. 相似文献
53.
Kento Morozumi Yoshihide Kawasaki Masamitsu Maekawa Shinya Takasaki Tomonori Sato Shuichi Shimada Naoki Kawamorita Shinichi Yamashita Koji Mitsuzuka Nariyasu Mano Akihiro Ito 《Cancer science》2022,113(1):182
To improve treatment outcomes in real practice, useful biomarkers are desired when predicting postoperative recurrence for renal cell carcinoma (RCC). We collected data from patients who underwent definitive surgery for RCC and for benign urological tumor at our department between November 2016 and December 2019. We evaluated the differences in pre‐ and postoperative urinary metabolites with our precise quantitative method and identified predictive factors for RCC recurrence. Additionally, to clarify the significance of metabolites, we measured the intracellular metabolite concentration of three RCC cell lines. Among the 56 patients with RCC, nine had a recurrence (16.0%). When comparing 27 patients with T1a RCC and 10 with benign tumor, a significant difference was observed between pre‐ and postoperative concentrations among 10 urinary metabolites. In these 10 metabolites, multiple logistic regression analysis identified five metabolites (lactic acid, glycine, 2‐hydroxyglutarate, succinic acid, and kynurenic acid) as factors to build our recurrence prediction model. The values of area under the receiver operating characteristic curve, sensitivity, and specificity in this predictive model were 0.894%, 88.9%, and 88.0%, respectively. When stratified into low and high risk groups of recurrence based on this model, we found a significant drop of recurrence‐free survival rates among the high risk group. In in vitro studies, intracellular metabolite concentrations of metastatic tumor cell lines were much higher than those of primary tumor cell lines. By using our quantitative evaluation of urinary metabolites, we could predict postoperative recurrence with high sensitivity and specificity. Urinary metabolites could be noninvasive biomarkers to improve patient outcome. 相似文献
54.
55.
56.
57.
Tomonori Sato Yoshihide Kawasaki Masamitsu Maekawa Shinya Takasaki Shuichi Shimada Kento Morozumi Masahiko Sato Naoki Kawamorita Shinichi Yamashita Koji Mitsuzuka Nariyasu Mano Akihiro Ito 《Cancer science》2020,111(7):2570-2578
Using surgically resected tissue, we identified characteristic metabolites related to the diagnosis and malignant status of clear cell renal cell carcinoma (ccRCC). Specifically, we quantified these metabolites in urine samples to evaluate their potential as clinically useful noninvasive biomarkers of ccRCC. Between January 2016 and August 2018, we collected urine samples from 87 patients who had pathologically diagnosed ccRCC and from 60 controls who were patients with benign urological conditions. Metabolite concentrations in urine samples were investigated using liquid chromatography‐mass spectrometry with an internal standard and adjustment based on urinary creatinine levels. We analyzed the association between metabolite concentration and predictability of diagnosis and of malignant status by multiple logistic regression and receiver operating characteristic (ROC) curves to establish ccRCC predictive models. Of the 47 metabolites identified in our previous study, we quantified 33 metabolites in the urine samples. Multiple logistic regression analysis revealed 5 metabolites (l ‐glutamic acid, lactate, d ‐sedoheptulose 7‐phosphate, 2‐hydroxyglutarate, and myoinositol) for a diagnostic predictive model and 4 metabolites (l ‐kynurenine, l ‐glutamine, fructose 6‐phosphate, and butyrylcarnitine) for a predictive model for clinical stage III/IV. The sensitivity and specificity of the diagnostic predictive model were 93.1% and 95.0%, respectively, yielding an area under the ROC curve (AUC) of 0.966. The sensitivity and specificity of the predictive model for clinical stage were 88.5% and 75.4%, respectively, with an AUC of 0.837. In conclusion, quantitative analysis of urinary metabolites yielded predictive models for diagnosis and malignant status of ccRCC. Urinary metabolites have the potential to be clinically useful noninvasive biomarkers of ccRCC to improve patient outcomes. 相似文献
58.
Nakamae H Shibayama H Kurokawa M Fukuda T Nakaseko C Kanda Y Nagai T Ohnishi K Maeda Y Matsuda A Amagasaki T Yanada M 《International journal of hematology》2011,93(5):624-632
Recent results from the phase 3 ENESTnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients) study have demonstrated superiority of nilotinib over imatinib for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (CML-CP). Here, we report results from the Japanese subset of patients in ENESTnd, and assess whether results in this subpopulation are consistent with the overall study population. Seventy-nine Japanese patients with CML-CP were randomized to receive nilotinib 300 mg twice daily (BID) (n = 30), nilotinib 400 mg BID (n = 24) or imatinib 400 mg once daily (QD) (n = 25). Major molecular response rates at 12 months, the primary endpoint, were at least twice as high for nilotinib 300 mg BID (57%) and nilotinib 400 mg BID (50%) compared with imatinib 400 mg QD (24%). No patient on nilotinib progressed, while one patient progressed on imatinib. Both drugs were generally well tolerated and discontinuations due to adverse events were comparable among treatment arms. The results in the subpopulation of Japanese patients from ENESTnd closely mirror the results of the overall population, and support the use of nilotinib at 300 mg BID in Japanese patients with newly diagnosed CML-CP. 相似文献
59.
Correlation Between Vascular Endothelial Growth Factor C Expression and Lymph Node Metastasis in T1 Carcinoma of the Colon and Rectum 总被引:11,自引:0,他引:11
Maeda K Yashiro M Nishihara T Nishiguchi Y Sawai M Uchima K Onoda N Ohira M Ishikawa T Hirakawa K 《Surgery today》2003,33(10):736-739
Purpose. Vascular endothelial growth factor C (VEGF-C) is known to be associated with the development of the lymphatic vessel system. Recently, VEGF-C is thought to be correlated with lymph node metastasis in some malignant tumors. In this study, we investigated the correlation between VEGF-C expression and lymph node metastasis in early carcinoma of the colon and rectum.
Methods. Two hundred and twenty-one endoscopically biopsied specimens from patients with T1 colorectal carcinoma prior to operation were investigated by an immunohistochemical study.
Results. VEGF-C expression was more frequently observed in the tumors with nodal metastasis than in those without metastasis. Moreover, a multivariate analysis indicated that VEGF-C expression is an independent predictor of lymph node metastasis.
Conclusion. VEGF-C staining using endoscopically biopsied specimens prior to operation could be of use in the prediction of lymph node metastasis and in preoperative selection of treatment in patients with T1 colorectal carcinoma. 相似文献
60.
Anthony M. Lynch Jennifer C. Sasaki Rosalie Elespuru David Jacobson‐Kram Véronique Thybaud Marlies De Boeck Marilyn J. Aardema Jiri Aubrecht R. Daniel Benz Stephen D. Dertinger George R. Douglas Paul A. White Patricia A. Escobar Albert Fornace Jr. Masamitsu Honma Russell T. Naven James F. Rusling Robert H. Schiestl Richard M. Walmsley Eiji Yamamura Jan van Benthem James H. Kim 《Environmental and molecular mutagenesis》2011,52(3):205-223
The International Life Sciences Institute (ILSI) Health and Environmental Sciences Institute (HESI) Project Committee on the Relevance and Follow‐up of Positive Results in In Vitro Genetic Toxicity (IVGT) Testing established an Emerging Technologies and New Strategies Workgroup to review the current State of the Art in genetic toxicology testing. The aim of the workgroup was to identify promising technologies that will improve genotoxicity testing and assessment of in vivo hazard and risk, and that have the potential to help meet the objectives of the IVGT. As part of this initiative, HESI convened a workshop in Washington, DC in May 2008 to discuss mature, maturing, and emerging technologies in genetic toxicology. This article collates the abstracts of the New and Emerging Technologies Workshop together with some additional technologies subsequently considered by the workgroup. Each abstract (available in the online version of the article) includes a section addressed specifically to the strengths, weaknesses, opportunities, and threats associated with the respective technology. Importantly, an overview of the technologies and an indication of how their use might be aligned with the objectives of IVGT are presented. In particular, consideration was given with regard to follow‐up testing of positive results in the standard IVGT tests (i.e., Salmonella Ames test, chromosome aberration assay, and mouse lymphoma assay) to add weight of evidence and/or provide mechanism of action for improved genetic toxicity risk assessments in humans. Environ. Mol. Mutagen., 2011. © 2010 Wiley‐Liss, Inc. 相似文献